Cardiawave
Cardiawave is dedicated to improving patient care through innovative non-invasive ultrasound therapies for cardiovascular diseases, particularly calcific aortic stenosis. Their mission is to develop breakthrough medical devices that offer effective, safe, and less invasive treatment options, reducing healthcare costs and enhancing quality of life for patients.
Industries
Nr. of Employees
small (1-50)
Cardiawave
3-5 rue Jules Guesde, 92300 Levallois-Perret, France
Patents
Process for testing the accuracy and the performance of an ultrasound transducer
US-12605569-B2
View DetailsUltrasonic processing apparatus comprising means for imaging cavitation bubbles
US-11571230-B2
View Details
Process for testing the accuracy and the performance of an ultrasound transducer
US-12605569-B2
View DetailsUltrasonic processing apparatus comprising means for imaging cavitation bubbles
US-11571230-B2
View DetailsProducts
Investigational non‑invasive focused ultrasound therapy device
A real‑time image‑guided medical device that delivers focused pulsed ultrasound (mechanical, non‑thermal) to soften calcified aortic valve leaflets and improve valve mobility; intended for clinical investigation.
Investigational non‑invasive focused ultrasound therapy device
A real‑time image‑guided medical device that delivers focused pulsed ultrasound (mechanical, non‑thermal) to soften calcified aortic valve leaflets and improve valve mobility; intended for clinical investigation.
Services
Design and conduct of first‑in‑human and pivotal multi‑center clinical investigations, including site selection, enrollment, monitoring and study reporting.
On‑site clinical engineering support, operator training, procedural assistance and feedback to R&D to optimize device usability and clinical workflows.
Design and implementation of control software, real‑time GUIs, integration of third‑party control components, and maintenance via CI/CD pipelines.
Implementation of a certified QMS, support for clinical trial authorizations, and participation in regulatory submission activities for market access.
Design and conduct of first‑in‑human and pivotal multi‑center clinical investigations, including site selection, enrollment, monitoring and study reporting.
On‑site clinical engineering support, operator training, procedural assistance and feedback to R&D to optimize device usability and clinical workflows.
Design and implementation of control software, real‑time GUIs, integration of third‑party control components, and maintenance via CI/CD pipelines.
Implementation of a certified QMS, support for clinical trial authorizations, and participation in regulatory submission activities for market access.
Expertise Areas
- Non‑invasive cardiovascular therapy development
- Focused ultrasound therapy R&D
- Clinical trial design and multi‑center execution
- Medical device software and image‑guided systems
Key Technologies
- Focused ultrasound therapy
- Pulsed cavitational ultrasound / shockwave generation
- Real‑time ultrasound image guidance
- Robotic/beam‑steering targeting of moving organs
News & Updates
Cardiawave presented positive 12-month results of its studies 'Valvosoft® FIM Study' and 'Valvosoft® Pivotal Study' at EuroPCR 2025.
A study published in The Lancet detailing the treatment of severe symptomatic aortic valve stenosis using Cardiawave's non-invasive ultrasound therapy.
Winner of Trophées de l’Embarqué 2025
Recognition at the Trophées de l’Embarqué 2025 for innovation.
Finalist at ICI Innovation Awards 2024
Finalist in the Innovation Awards at ICI Meeting 2024.
Recognition by Inserm as a major breakthrough of 2023
Inserm recognized Cardiawave's technology as one of its major breakthroughs in 2023.
Cardiawave presented positive 12-month results of its studies 'Valvosoft® FIM Study' and 'Valvosoft® Pivotal Study' at EuroPCR 2025.
A study published in The Lancet detailing the treatment of severe symptomatic aortic valve stenosis using Cardiawave's non-invasive ultrasound therapy.
Winner of Trophées de l’Embarqué 2025
Recognition at the Trophées de l’Embarqué 2025 for innovation.
Finalist at ICI Innovation Awards 2024
Finalist in the Innovation Awards at ICI Meeting 2024.
Recognition by Inserm as a major breakthrough of 2023
Inserm recognized Cardiawave's technology as one of its major breakthroughs in 2023.